Physician profile
Daniel Callaghan
NPI 1124032941
$523.40
in general payments reported to CMS, 2019-2025
12 companies · $220 in 2025
The $220 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $11.56 · 2022: $97.50 · 2023: $46.55 · 2024: $30.79 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $297.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $159.41 | 2019-2025 | Breztri |
| Baxter Healthcare | $78.05 | 2022 | |
| Abbvie INC. | $54.23 | 2024-2025 | |
| Glaxosmithkline, LLC. | $48.83 | 2022-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $45.13 | 2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $32.56 | 2025 | Wegovy |
| Amgen INC. | $24.53 | 2025 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $21.34 | 2025 | |
| Inspire Medical Systems, INC. | $19.14 | 2025 | Inspire |
| Kerecis Limited | $17.17 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Pfizer INC. | $15.25 | 2025 | |
| Echosens North America, INC. | $7.76 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Callaghan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.